Italian expert consensus for the management of actinic keratosis in immunocompetent patients

K. Peris, P. G. Calzavara-Pinton, L. Neri, G. Girolomoni, G. Malara, A. Parodi, S. Piaserico, R. Rossi, G. Pellacani

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Actinic keratosis (AK) is a common skin disease which can potentially progress to invasive squamous cell carcinoma (iSCC). Given that mortality rates and health-care cost associated with iSCC are substantial, the management of AK represents an important public health issue. Several effective lesion-directed and field-directed treatments are available. Ablative procedures (e.g. cryosurgery, excision, laser ablation, curettage alone or with electrodessication) are considered cost-effective options for solitary lesions. Field-directed therapies (e.g. Ingenol Mebutate, imiquimod, PDT, 5-Fluorouracile, diclofenac 3%, 5-FU + Salicylic acid) can be used over large epidermal surfaces and are directed to treat both individual visible lesions and cancerization fields. In order to provide guidance for management choice in clinical practice, several guidelines concerning the diagnosis and treatment of AK have been published in the past decade. However, the introduction of novel therapeutic options requires continuous updates of recommendations and adaptation to national contexts. The present review summarizes the existing evidence and reports the results of a consensus workshop on the management of AK.

Original languageEnglish
Pages (from-to)1077-1084
Number of pages8
JournalJournal of the European Academy of Dermatology and Venereology
Volume30
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Actinic Keratosis
imiquimod
Squamous Cell Carcinoma
Consensus Development Conferences
Cryosurgery
Salicylic Acid
Curettage
Diclofenac
Laser Therapy
Therapeutics
Practice Guidelines
Skin Diseases
Fluorouracil
Health Care Costs
Public Health
Costs and Cost Analysis
Mortality

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Italian expert consensus for the management of actinic keratosis in immunocompetent patients. / Peris, K.; Calzavara-Pinton, P. G.; Neri, L.; Girolomoni, G.; Malara, G.; Parodi, A.; Piaserico, S.; Rossi, R.; Pellacani, G.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 30, No. 7, 01.07.2016, p. 1077-1084.

Research output: Contribution to journalReview article

Peris, K, Calzavara-Pinton, PG, Neri, L, Girolomoni, G, Malara, G, Parodi, A, Piaserico, S, Rossi, R & Pellacani, G 2016, 'Italian expert consensus for the management of actinic keratosis in immunocompetent patients', Journal of the European Academy of Dermatology and Venereology, vol. 30, no. 7, pp. 1077-1084. https://doi.org/10.1111/jdv.13648
Peris, K. ; Calzavara-Pinton, P. G. ; Neri, L. ; Girolomoni, G. ; Malara, G. ; Parodi, A. ; Piaserico, S. ; Rossi, R. ; Pellacani, G. / Italian expert consensus for the management of actinic keratosis in immunocompetent patients. In: Journal of the European Academy of Dermatology and Venereology. 2016 ; Vol. 30, No. 7. pp. 1077-1084.
@article{253bb8de236641d99de3c9fb411ba262,
title = "Italian expert consensus for the management of actinic keratosis in immunocompetent patients",
abstract = "Actinic keratosis (AK) is a common skin disease which can potentially progress to invasive squamous cell carcinoma (iSCC). Given that mortality rates and health-care cost associated with iSCC are substantial, the management of AK represents an important public health issue. Several effective lesion-directed and field-directed treatments are available. Ablative procedures (e.g. cryosurgery, excision, laser ablation, curettage alone or with electrodessication) are considered cost-effective options for solitary lesions. Field-directed therapies (e.g. Ingenol Mebutate, imiquimod, PDT, 5-Fluorouracile, diclofenac 3{\%}, 5-FU + Salicylic acid) can be used over large epidermal surfaces and are directed to treat both individual visible lesions and cancerization fields. In order to provide guidance for management choice in clinical practice, several guidelines concerning the diagnosis and treatment of AK have been published in the past decade. However, the introduction of novel therapeutic options requires continuous updates of recommendations and adaptation to national contexts. The present review summarizes the existing evidence and reports the results of a consensus workshop on the management of AK.",
author = "K. Peris and Calzavara-Pinton, {P. G.} and L. Neri and G. Girolomoni and G. Malara and A. Parodi and S. Piaserico and R. Rossi and G. Pellacani",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/jdv.13648",
language = "English",
volume = "30",
pages = "1077--1084",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "7",

}

TY - JOUR

T1 - Italian expert consensus for the management of actinic keratosis in immunocompetent patients

AU - Peris, K.

AU - Calzavara-Pinton, P. G.

AU - Neri, L.

AU - Girolomoni, G.

AU - Malara, G.

AU - Parodi, A.

AU - Piaserico, S.

AU - Rossi, R.

AU - Pellacani, G.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Actinic keratosis (AK) is a common skin disease which can potentially progress to invasive squamous cell carcinoma (iSCC). Given that mortality rates and health-care cost associated with iSCC are substantial, the management of AK represents an important public health issue. Several effective lesion-directed and field-directed treatments are available. Ablative procedures (e.g. cryosurgery, excision, laser ablation, curettage alone or with electrodessication) are considered cost-effective options for solitary lesions. Field-directed therapies (e.g. Ingenol Mebutate, imiquimod, PDT, 5-Fluorouracile, diclofenac 3%, 5-FU + Salicylic acid) can be used over large epidermal surfaces and are directed to treat both individual visible lesions and cancerization fields. In order to provide guidance for management choice in clinical practice, several guidelines concerning the diagnosis and treatment of AK have been published in the past decade. However, the introduction of novel therapeutic options requires continuous updates of recommendations and adaptation to national contexts. The present review summarizes the existing evidence and reports the results of a consensus workshop on the management of AK.

AB - Actinic keratosis (AK) is a common skin disease which can potentially progress to invasive squamous cell carcinoma (iSCC). Given that mortality rates and health-care cost associated with iSCC are substantial, the management of AK represents an important public health issue. Several effective lesion-directed and field-directed treatments are available. Ablative procedures (e.g. cryosurgery, excision, laser ablation, curettage alone or with electrodessication) are considered cost-effective options for solitary lesions. Field-directed therapies (e.g. Ingenol Mebutate, imiquimod, PDT, 5-Fluorouracile, diclofenac 3%, 5-FU + Salicylic acid) can be used over large epidermal surfaces and are directed to treat both individual visible lesions and cancerization fields. In order to provide guidance for management choice in clinical practice, several guidelines concerning the diagnosis and treatment of AK have been published in the past decade. However, the introduction of novel therapeutic options requires continuous updates of recommendations and adaptation to national contexts. The present review summarizes the existing evidence and reports the results of a consensus workshop on the management of AK.

UR - http://www.scopus.com/inward/record.url?scp=84976487385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976487385&partnerID=8YFLogxK

U2 - 10.1111/jdv.13648

DO - 10.1111/jdv.13648

M3 - Review article

C2 - 27060910

AN - SCOPUS:84976487385

VL - 30

SP - 1077

EP - 1084

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 7

ER -